Last updated: August 14, 2024
Sponsor: Gangnam Severance Hospital
Overall Status: Active - Recruiting
Phase
N/A
Condition
Malignant Ascites
Fever
Peritoneal Cancer
Treatment
Arm I (QL block and multimodal analgesia), Arm II (multimodal analgesia without regional block)
Clinical Study ID
NCT05597683
3-2022-0328
Ages > 19 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Adult patients who are scheduled to undergo cytoreductive surgery and hyperthermicintra-peritoneal chemotherapy (CRS and HIPEC)
Exclusion
Exclusion Criteria:
Allergy to local anesthetics or fentanyl
Chronic pain
Drug abuse
Patients who are unable to use patient-controlled analgesia
Skin infection at site for quadratus lomborum block
pregnant or breatfeeding women
Patients who are unable to communicate
Study Design
Total Participants: 50
Treatment Group(s): 1
Primary Treatment: Arm I (QL block and multimodal analgesia), Arm II (multimodal analgesia without regional block)
Phase:
Study Start date:
November 15, 2022
Estimated Completion Date:
January 10, 2025
Study Description
Connect with a study center
Gangnam Severance Hospital
Seoul,
Korea, Republic ofActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.